Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide and eating symptoms

A 60-week placebo-controlled trial examined eating attitudes and behaviours during semaglutide treatment in adults seeking obesity care.

Why we wrote this. Eating-disorder outcomes deserve precise reporting: this trial is encouraging in places, but it does not screen, diagnose or clear an individual.

In this article (5 sections)
  1. What the trial did
  2. What changed in the study groups
  3. Why the safety wording is careful
  4. What this study cannot answer
  5. Reading the result without overclaiming

A 60-week randomised, placebo-controlled study examined eating attitudes and behaviours among adults seeking obesity treatment who received semaglutide or placebo alongside lifestyle intervention. It found greater improvement in several measured eating-related outcomes with semaglutide, while also reporting that disordered behaviours were rare but did occur. The publication offers evidence about a defined group, not a diagnostic tool or a universal safety conclusion.[1]

The distinction matters. An eating disorder is a clinical condition assessed through appropriate professional evaluation. A questionnaire score, an episode of loss of control over eating or concern about body shape can be clinically important, but none alone settles a diagnosis. Medication decisions for people with current or past eating-disorder symptoms need individual assessment, not a conclusion drawn from a headline.

What the trial did

The trial enrolled 120 individuals seeking obesity treatment with BMI above 27 kg/m². Participants were randomised in a 3:2 ratio to semaglutide 2.4 mg or placebo for 60 weeks; both groups received lifestyle intervention. Assessments occurred at baseline and weeks 20, 40 and 60. Clinicians evaluated binge eating and eating-disorder psychopathology, while questionnaires assessed loss of control over eating, drive for thinness, body dissatisfaction and mood.[1]

Randomisation and a placebo comparison can reduce allocation and expectation bias, but they do not make every result broadly transferable. The study population consisted of adults already seeking obesity treatment. The design does not establish results for adolescents, for people not seeking such treatment, or for every type and severity of eating disorder. The registered study is NCT05548647.[2]

What changed in the study groups

The authors report significantly greater reductions with semaglutide at several time points in loss of control, global eating-disorder psychopathology, weight and shape concern, drive for thinness and body dissatisfaction. The groups did not differ significantly in reductions in binge frequency. That difference is important: a change in some related measures is not the same finding as a demonstrated difference in every eating behaviour measured.[1]

Among participants who reported binge episodes at baseline, and among those with full or subthreshold binge-eating disorder, the paper reports that abstinence was more likely with semaglutide than with placebo. Those are subgroup findings within a relatively small trial, not evidence that semaglutide is an established stand-alone treatment for binge-eating disorder. The trial's title, population and outcomes should stay attached to the result.[1]

Why the safety wording is careful

The paper reports that reliable deterioration in eating psychopathology, new onset of binge eating and compensatory behaviours were rare, and that symptom emergence did not appear higher with semaglutide. It also says disordered eating behaviours did occur and suggests periodic monitoring in at-risk individuals. Rare in this study does not mean impossible, harmless or absent outside it.[1]

For someone with distress around food, eating or body image, that framing supports attention rather than reassurance by default. A change in eating patterns, restriction, bingeing, purging, mood or distress should be discussed with an appropriate healthcare professional. This article cannot judge a person's symptoms or tell them whether to begin, continue or stop treatment.

What this study cannot answer

The trial cannot prove that semaglutide prevents eating disorders, cures binge-eating disorder or is suitable for every person with a history of disordered eating. It also cannot separate the medicine from all effects of the accompanying lifestyle intervention, contact with clinicians and the context of participation. The authors' result is a useful signal within the studied setting, with monitoring still warranted.[1]

It is also distinct from regulatory status. The site's semaglutide regulation page addresses product and jurisdiction context; our semaglutide overview explains the medicine's place in the GLP-1 class. Neither page replaces an eating-disorder assessment or mental-health support.

The article's limits are as important as its positive findings. A trial report cannot capture every pattern of eating distress, all durations of treatment or every care setting. Readers who want context can separately review semaglutide mechanism, semaglutide safety, semaglutide evidence and semaglutide regulation. Those links provide topic context only; they do not assess eating symptoms or replace direct care.

The authors also used repeated assessments rather than a single questionnaire. That approach can describe change over time, but it still does not replace an individual clinical review.

Reading the result without overclaiming

The most defensible summary is narrow: in 120 adults seeking obesity care, over 60 weeks and with lifestyle intervention in both groups, semaglutide was associated with greater improvement in several measured eating-related outcomes than placebo. It was not associated with a significantly different reduction in binge frequency, and rare problematic behaviours still occurred. That is more informative than either a blanket claim of benefit or a blanket claim of risk.

The peptide regulation hub and semaglutide news coverage can help readers keep trial findings, approval status and new reporting separate. Anyone concerned about eating symptoms deserves direct, professional support rather than an online interpretation of a study.

Frequently asked

Did semaglutide stop binge eating in this trial?

The groups did not differ significantly in reductions in binge frequency. The paper reported higher abstinence in specified baseline subgroups, which is not the same as proving a general treatment effect for everyone with binge eating.

Did the study include people with eating disorders?

It included adults seeking obesity treatment, including some with binge episodes or full or subthreshold binge-eating disorder. Its results do not apply automatically to all diagnoses or levels of clinical severity.

Does this prove semaglutide is safe for eating disorders?

No. The study reported rare but present disordered behaviours and recommended monitoring in at-risk individuals. Individual risk needs clinical assessment.

What should I do if food or body-image symptoms are worsening?

Seek timely support from an appropriate healthcare professional or eating-disorder service. Do not use this study as a reason to self-adjust prescribed treatment.

Sources

  1. [1]Allison et al. Disordered Eating Attitudes and Behaviors in Individuals Treated by Semaglutide: 60-Week Randomized Placebo-Controlled Trial (2026; PMID 43035836)Tier 1 · primary↩
  2. [2]Semaglutide eating attitudes and behaviors study record, NCT05548647 (ClinicalTrials.gov)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars